AASLD – The Liver Meeting 2022 Conference news bulletinRead our summary bulletin of news from the conference in English, Russian, Spanish, French and Portuguese. Ronald Rampsch/Shutterstock.comHepatitis C eliminationOnly 11 countries on target to eliminate hepatitis C by 2030. Anastasiia Chepinska/UnsplashMother-to-child transmissionSimplified tenofovir regimen as effective as recommended preventive treatment in pregnant women with hepatitis B. infohep news Hepatitis C elimination Only 11 countries on target to eliminate hepatitis C by 2030 Keith Alcorn / 15 November 2022 Only 11 countries are on course to meet their goals for elimination of hepatitis C by 2030, while five countries with the highest burdens of hepatitis C are unlikely to achieve elimination ... Treatment for people who use drugs UK community test-and-treat service achieves high hepatitis C cure rate in people who use drugs Keith Alcorn / 15 November 2022 Offering hepatitis C testing and treatment through a community drugs and alcohol service led to high uptake of testing and treatment among current and former injecting drug users, as well as a ... Mother to child Simplified tenofovir regimen as effective as recommended preventive treatment in pregnant women with hepatitis B Keith Alcorn / 14 November 2022 A simplified regimen for the prevention of mother-to-child transmission of hepatitis B was just as effective as the standard preventive regimen in pregnant women with very high virus levels and is likely ... New and experimental treatments for hepatitis B VIR-2218 combined with monoclonal antibody or pegylated interferon delivers potent suppression of hepatitis B Keith Alcorn / 14 November 2022 The experimental hepatitis B antiviral VIR-2218 shows potent activity against the virus when combined with either a monoclonal antibody that targets three steps in the hepatitis B lifecycle, or pegylated interferon, two studies ... New and experimental treatments for hepatitis B Bepirovirsen treatment leads to sustained loss of hepatitis B markers for up to one in five Keith Alcorn / 14 November 2022 Up to one in five people with hepatitis B treated with the experimental antiviral bepirovirsen achieved a sustained loss of hepatitis B surface antigen (HBsAg) and HBV DNA, a sign indicating the ... View more > Editors' picks from other sources View more > Other pages in this section Latest news All the news Conference news Email bulletin archive